KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Cash: 2011-2025

Historic Change in Cash for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $35.8 million.

  • Travere Therapeutics' Change in Cash rose 768.77% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.5 million, marking a year-over-year increase of 169.11%. This contributed to the annual value of $359,000 for FY2024, which is 110.22% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Change in Cash is $35.8 million, which was up 169.86% from $13.3 million recorded in Q2 2025.
  • Travere Therapeutics' Change in Cash's 5-year high stood at $99.7 million during Q1 2023, with a 5-year trough of -$90.5 million in Q2 2023.
  • Its 3-year average for Change in Cash is $4.5 million, with a median of $4.1 million in 2024.
  • Per our database at Business Quant, Travere Therapeutics' Change in Cash skyrocketed by 1,284.68% in 2021 and then tumbled by 681.16% in 2022.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Change in Cash stood at $15.4 million in 2021, then slumped by 681.16% to -$89.6 million in 2022, then rose by 3.99% to -$86.1 million in 2023, then surged by 125.71% to $22.1 million in 2024, then spiked by 768.77% to $35.8 million in 2025.
  • Its Change in Cash stands at $35.8 million for Q3 2025, versus $13.3 million for Q2 2025 and $3.4 million for Q1 2025.